State of the Art in Incremental Forming: Process Variants, Tooling, Industrial Applications for Complex Part Manufacturing and Sustainability of the Process.

This paper explores the development and application of the incremental forming process, an innovative method for manufacturing complex parts with high flexibility and low tooling costs. The review categorizes three key process variants: Single Point Incremental Forming (SPIF), Two Point Incremental Forming (TPIF), and Incremental Forming with Conjugated Active Plate (IFCAP). This study demonstrates the significant effects of these process variants on part accuracy and material behavior, particularly under varying process conditions.

Gliosarcoma: A Multi-Institutional Analysis on Clinical Outcomes and Prognostic Factors.

Purpose: This study describes oncological outcomes and investigates prognostic factors for patients with gliosarcomas (GSM).

Methods: Histopathologically confirmed GSM patients who underwent treatment at five European institutions were retrospectively analyzed.

Results: We analyzed 170 patients with a median clinical follow-up time of 9.

Incidence of hippocampal and perihippocampal brain metastases and impact on hippocampal-avoiding radiotherapy: A systematic review and meta-analysis.

Background And Purpose: In patients requiring prophylactic cranial irradiation (PCI) or whole-brain radiotherapy (WBRT) for brain metastases (BMs), hippocampal avoidance (HA) has been shown to preserve neurocognitive function and quality of life. Here, we aim to estimate the incidence of hippocampal and perihippocampal BMs and the subsequent risk of local undertreatment in patients undergoing hippocampal sparing radiotherapy.

Materials And Methods: MEDLINE, Embase, and Scopus were searched with the terms "Hippocampus", "Brain Neoplasms", and related terms.

Dummy run for planning of isotoxic dose-escalated radiation therapy for glioblastoma used in the PRIDE trial (NOA-28; ARO-2024-01; AG-NRO-06).

Background: The PRIDE trial (NOA-28; ARO-2024-01; AG-NRO-06; NCT05871021) is designed to determine whether a dose escalation with 75.0 Gy in 30 fractions can enhance the median overall survival (OS) in patients with methylguanine methyltransferase (MGMT) promotor unmethylated glioblastoma compared to historical median OS rates, while being isotoxic to historical cohorts through the addition of concurrent bevacizumab (BEV). To ensure protocol-compliant irradiation planning with all study centers, a dummy run was planned and the plan quality was evaluated.

Proteomic Analysis of Spatial Heterogeneity Identifies HMGB2 as Putative Biomarker of Tumor Progression in Adult-Type Diffuse Astrocytomas.

Although grading is defined by the highest histological grade observed in a glioma, most high-grade gliomas retain areas with histology reminiscent of their low-grade counterparts. We sought to achieve the following: (i) identify proteins and molecular pathways involved in glioma evolution; and (ii) validate the high mobility group protein B2 (HMGB2) as a key player in tumor progression and as a prognostic/predictive biomarker for diffuse astrocytomas. We performed liquid chromatography tandem mass spectrometry (LC-MS/MS) in multiple areas of adult-type astrocytomas and validated our finding in multiplatform-omics studies and high-throughput IHC analysis.